Chronic pain intervention using pulsed shortwave t
Post# of 8512
(Total Views: 373)
Posted On: 06/03/2019 11:11:18 AM
Chronic pain intervention using pulsed shortwave therapy
https://apnews.com/NewMediaWire/7732388620bb3...d9d1fd2cda
Finally some news goes out to the world rather than in an email to shareholders.
2 hours ago
Frederick, MD - ( NewMediaWire ) - June 3, 2019 - BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased to announce the publication of a registry study in the May 2019 edition of the Journal of Pain Management. Titled “Chronic pain intervention using pulsed shortwave therapy: the relationship between pain demographics and central sensitization inventory”, the study found that ActiPatch® reduced chronic pain linked to central sensitization by 41.6%, in a sample of 174 people. Further, the study found that the level of central sensitization in subjects (Central Sensitization Inventory) is strongly correlated with their baseline pain levels, among other demographics.
As a side note, the Company has filed its response to the FDA’s request for additional information on the postoperative pain 510(k) application on May 29, 2019.
https://apnews.com/NewMediaWire/7732388620bb3...d9d1fd2cda
Finally some news goes out to the world rather than in an email to shareholders.
2 hours ago
Frederick, MD - ( NewMediaWire ) - June 3, 2019 - BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased to announce the publication of a registry study in the May 2019 edition of the Journal of Pain Management. Titled “Chronic pain intervention using pulsed shortwave therapy: the relationship between pain demographics and central sensitization inventory”, the study found that ActiPatch® reduced chronic pain linked to central sensitization by 41.6%, in a sample of 174 people. Further, the study found that the level of central sensitization in subjects (Central Sensitization Inventory) is strongly correlated with their baseline pain levels, among other demographics.
As a side note, the Company has filed its response to the FDA’s request for additional information on the postoperative pain 510(k) application on May 29, 2019.
(0)
(0)